The pleiotropic role of galectin-3 in melanoma progression: Unraveling the enigma

Adv Cancer Res. 2023:157:157-193. doi: 10.1016/bs.acr.2022.06.001. Epub 2022 Aug 8.

Abstract

Melanoma is a highly aggressive skin cancer with poor outcomes associated with distant metastasis. Intrinsic properties of melanoma cells alongside the crosstalk between melanoma cells and surrounding microenvironment determine the tumor behavior. Galectin-3 (Gal-3), a ß-galactoside-binding lectin, has emerged as a major effector in cancer progression, including melanoma behavior. Data from melanoma models and patient studies reveal that Gal-3 expression is dysregulated, both intracellularly and extracellularly, throughout the stages of melanoma progression. This review summarizes the most recent data and hypotheses on Gal-3 and its tumor-modulating functions, highlighting its role in driving melanoma growth, invasion, and metastatic colonization. It also provides insight into potential Gal-3-targeted strategies for melanoma diagnosis and treatment.

Keywords: Cancer glycobiology; Galectins; Melanoma; Metastasis; Microenvironment; Therapy.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Galectin 3* / metabolism
  • Humans
  • Melanoma* / pathology
  • Tumor Microenvironment

Substances

  • Galectin 3